

**AMENDMENT UNDER 37 C.F.R. § 1.111**

**Application No.: 09/744,550**

**Atty Docket No.: Q62780**

**AMENDMENTS TO THE CLAIMS**

**This listing of claims will replace all prior versions and listings of claims in the application:**

**LISTING OF CLAIMS:**

Claims 1 to 21. (canceled).

Claim 22. (withdrawn): A ~~Nuclear~~nuclear magnetic resonance method, comprising administering a drug composition containing a compound which comprises at least one member selected from the group consisting of  $-^{17}\text{OH}$ ,  $-^{14}\text{NH}$  and  $^{33}\text{SH}$  in its chemical structure, and detecting a biodistribution of the compound with a H proton as a detection nucleus.

Claim 23. (withdrawn): The nuclear magnetic resonance method according to claim 22, wherein the drug composition is selected from the group consisting of therapeutic agents, nutritional tonic agents, infusions and diagnostic agents.

Claim 24. (withdrawn): The nuclear magnetic resonance method according to claim 22, wherein the compound which comprises at least one member selected from the group consisting of  $-^{17}\text{OH}$ ,  $-^{14}\text{NH}$  and  $-^{33}\text{SH}$  in its chemical structure is sugar, amino acid, or additive or solvent of the drug composition.

Claim 25. (withdrawn): The nuclear magnetic resonance method according to claim 24, wherein the compound which comprises at least one member selected from the group consisting of  $-^{17}\text{OH}$ ,  $-^{14}\text{NH}$  and  $^{33}\text{SH}$  in its chemical structure is sugar and wherein the sugar is glucose.

**AMENDMENT UNDER 37 C.F.R. § 1.111**

**Application No.: 09/744,550**

**Atty Docket No.: Q62780**

Claim 26. (withdrawn): The nuclear magnetic resonance method according to claim 24, wherein the compound which comprises at least one member selected from the group consisting of  $-^{17}\text{OH}$ ,  $-^{14}\text{NH}$  and  $^{33}\text{SH}$  in its chemical structure is a solvent of the drug composition and wherein the solvent is an aqueous solvent.

Claim 27. (withdrawn): The nuclear magnetic resonance method according to claim 26, wherein the aqueous solvent is water.

Claim 28. (withdrawn): The nuclear magnetic resonance method according to claim 22, wherein the drug composition contains a material for a drug delivery system.

Claim 29. (withdrawn): The nuclear magnetic resonance method according to claim 28, wherein the material for a drug delivery system is a liposome.

Claim 30. (withdrawn): A method for confirming a biodistribution of a drug composition, comprising administering the drug composition wherein the compound which comprises at least one member selected from the group consisting of  $-^{17}\text{OH}$ ,  $-^{14}\text{NH}$  and  $^{33}\text{SH}$  in its chemical structure in advance of a full-scale administration of the drug composition, and detecting the biodistribution of the compound with a H proton as a detection nucleus.

Claim 31. (withdrawn): The method for confirming a biodistribution of a drug composition according to claim 30, wherein the drug composition is selected from the group consisting of therapeutic drugs and diagnostic drugs.

Claim 32. (withdrawn): The method for confirming a biodistribution of a drug composition according to claim 30, wherein the compound which comprises at least one member

**AMENDMENT UNDER 37 C.F.R. § 1.111**

**Application No.: 09/744,550**

**Atty Docket No.: Q62780**

selected from the group consisting of  $-^{17}\text{OH}$ ,  $-^{14}\text{NH}$  and  $-^{33}\text{SH}$  in its chemical structure is an active ingredient of the drug composition.

Claim 33. (withdrawn): The method for confirming a biodistribution of a drug composition according to claim 32, wherein the active ingredient of the drug composition is sugar or amino acid.

Claim 34. (withdrawn): The method for confirming a biodistribution of a drug composition according to claim 33, wherein the active ingredient is sugar and wherein the sugar is glucose.

Claim 35. (canceled).

Claim 36. (currently amended): A drug composition comprising an active ingredient of at least one medicament selected from the group consisting of therapeutic agents, nutritional tonic agents, infusions and diagnostic agents, dissolved in a solvent,

wherein the solvent comprises at least one  $-^{17}\text{OH}$  in its chemical structure, and  $^{17}\text{O}$  in the  $-^{17}\text{OH}$  exerts a relaxation effect on the H proton bonded thereto and the relaxation effect spreads through the exchange of a proton in a vital component of a target organ or tissue of a living body with said H proton bonded to the  $^{17}\text{O}$ , thereby enabling detection by nuclear magnetic resonance; and,

a concentration of the active ingredient in the resulting drug composition is equal to a concentration of the active ingredient in the administrative form of the medicament.

Claim 37. (currently amended): The drug composition according to claim ~~35~~ or 36, wherein the solvent is an aqueous solvent.

**AMENDMENT UNDER 37 C.F.R. § 1.111**

**Application No.: 09/744,550**

**Atty Docket No.: Q62780**

Claim 38. (previously presented): The drug composition according to claim 37 wherein the aqueous solvent is water.

Claim 39. (currently amended): The drug composition according to claim ~~35 or~~ 36, wherein the composition contains a material for a drug delivery system.

Claim 40. (currently amended): A drug composition comprising an active ingredient of at least one medicament selected from the group consisting of therapeutic agents, nutritional tonic agents, infusions and diagnostic agents, dissolved in a solvent,

wherein the active ingredient of the medicament contains a compound comprising ~~at least either one of~~  $^{14}\text{NH}$  or  $^{33}\text{SH}$  in its chemical structure, and  $^{14}\text{N}$  or  $^{33}\text{S}$  in the  $^{14}\text{NH}$  or  $^{33}\text{SH}$  exerts a relaxation effect on the H proton bonded thereto and the relaxation effect spreads through the exchange of a proton in a vital component of a target organ or tissue of a living body with said H proton bonded to the  $^{14}\text{N}$  or  $^{33}\text{S}$ , thereby enabling detection by nuclear magnetic resonance.

Claim 41. (currently amended): A drug composition comprising an active ingredient of at least one medicament selected from the group consisting of therapeutic agents, nutritional tonic agents, infusions and diagnostic agents, dissolved in a solvent,

wherein the active ingredient of the medicament contains a compound comprising ~~at least either one of~~  $^{14}\text{NH}$  or  $^{33}\text{SH}$  in its chemical structure, and  $^{14}\text{N}$  or  $^{33}\text{S}$  in the  $^{14}\text{NH}$  or  $^{33}\text{SH}$  exerts a relaxation effect on the H proton bonded thereto and the relaxation effect spreads through the exchange of a proton in a vital component of a target organ or tissue of a living body

**AMENDMENT UNDER 37 C.F.R. § 1.111**

**Application No.: 09/744,550**

**Atty Docket No.: Q62780**

with said H proton bonded to the  $^{14}\text{N}$  or  $^{33}\text{S}$ , thereby enabling detection by nuclear magnetic resonance; and

a concentration of the active ingredient in the resulting drug composition is equal to a concentration of the active ingredient in the administrative form of the medicament.

Claim 42. (currently amended): The drug composition according to claim 40 or 41, wherein the compound comprising at least either one of  $^{14}\text{NH}$  or  $^{33}\text{SH}$  in its chemical structure is an amino acid.

Claim 43. (previously presented): The drug composition according to claim 40 or 41, wherein the composition contains a material for a drug delivery system.